Te recently founded company ADx NeuroSciences NV entered into a license agreement with K.U.Leuven, the academic founder of ADx NeuroSciences. The license agreement grants ADx NeuroSciences exclusive worldwide rights to further develop and commercialise certain antibodies which selectively bind phosphorylated Tau aggregates. ADx NeuroSciences is a new biotech company that focuses on the development of novel (bio)markers for use in the diagnosis of dementia, such as Alzheimer’s, Parkinson’s and other neurodegenerative diseases.
Current tests to diagnose patients with Alzheimer’s disease are unable to indicate the prognosis of the disease. As a consequence, the pharma industry as well as clinicians will urgently need novel markers to be able to identify patients and to predict how the disease evolves. In response to this demand, ADx NeuroSciences aims to commercialise diagnostic products for neurodegenerative disorders that are developed in close collaboration with pharma.
”This license agreement is an important step for the development of ADx NeuroSciences to further create value as well as in the establishment of a solid and long-term relationship and alliance with K.U.Leuven”, says Koen Dewaele, CEO of ADx NeuroSciences.
“We are pleased to support ADx NeuroSciences by providing it with a strong intellectual property position”, says Prof. Joris Winderickx, chair of the Leuven Bio-Science, Bio-Engineering and Bio-Technology Centre, K.U.Leuven. “This license agreement puts ADx NeuroSciences in pole position to unravel the role of Tau pathology – Tau is a hallmark in the AD process – in the diagnosis of Alzheimer’s disease.”
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
